Jonas S Heitmann - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Jonas S Heitmann

Showing results (61-70 of 66) with videos related to

Pageof 7

Sort By:

You have reached the last page of results.This site can display upto 66 results.

Nature Communications|October 27, 2022

The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinomaJens Bauer, Natalie Köhler, Yacine Maringer, et al.

Blood Cancer Discovery|October 17, 2023

Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor CellsAnnika Nelde, Heiko Schuster, Jonas S Heitmann, et al.

The Lancet. Haematology|January 17, 2026

Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 studyJonas S Heitmann, Yacine Maringer, Susanne Jung, et al.

Nature Communications|February 20, 2021

Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivityMatthias Becker, Monika Strengert, Daniel Junker, et al.

Nature Immunology|October 1, 2020

SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognitionAnnika Nelde, Tatjana Bilich, Jonas S Heitmann, et al.

Nature Communications|August 18, 2023

Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiencyJonas S Heitmann, Claudia Tandler, Maddalena Marconato, et al.

Pageof 7

Search research articles

Showing results (61-70 of 66) with videos related to

Sort By:

Pageof 7

You have reached the last page of results.This site can display upto 66 results.

Nature Communications|October 27, 2022

The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinomaJens Bauer, Natalie Köhler, Yacine Maringer, et al.

Blood Cancer Discovery|October 17, 2023

Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor CellsAnnika Nelde, Heiko Schuster, Jonas S Heitmann, et al.

The Lancet. Haematology|January 17, 2026

Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 studyJonas S Heitmann, Yacine Maringer, Susanne Jung, et al.

Nature Communications|February 20, 2021

Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivityMatthias Becker, Monika Strengert, Daniel Junker, et al.

Nature Immunology|October 1, 2020

SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognitionAnnika Nelde, Tatjana Bilich, Jonas S Heitmann, et al.

Nature Communications|August 18, 2023

Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiencyJonas S Heitmann, Claudia Tandler, Maddalena Marconato, et al.

Pageof 7